Brent Boyce, MD
Dermatology · Sebewaing, MINPI 1417944786
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,105 of the $171,061 with a category attached, or 80.7%. 36 manufacturers reported payments, led by AbbVie at 45.7% of the total. Reporting peaked in 2023 at $39,272 and has fallen 72.4% since, to $10,853 in 2025. Among dermatology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,484 payments — averaging $115.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$78K
- Johnson & Johnson$65K
- Janssen Scientific Affairs, LLC$12K
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$3K
- Sun Pharmaceutical Industries Inc.$2K
- Novartis$2K
- plus $9K from 30 others
Across 560 payments — averaging $3742.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$929K
- AbbVie$357K
- Pfizer$281K
- Incyte Corporation$249K
- Regeneron$53K
- Amgen$49K
- plus $178K from 11 others
What the payments were for
- Consulting fees$1,8001%
- Speaking & faculty fees$138,10581%
- Travel & lodging$5,2153%
- Food & beverage$24,55914%
- Education$1,3821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 288 | $78,156 |
| Johnson & Johnson(2 entities) | 330 | $64,903 |
| Janssen Scientific Affairs, LLC | 15 | $11,902 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 47 | $2,635 |
| Sun Pharmaceutical Industries Inc. | 127 | $2,204 |
| Novartis | 143 | $1,940 |
| Sanofi | 62 | $1,302 |
| UCB, Inc. | 66 | $1,212 |
| Lilly USA, LLC | 54 | $903 |
| Regeneron Healthcare Solutions, Inc. | 39 | $894 |
| Amgen | 43 | $855 |
| Boehringer Ingelheim | 31 | $661 |
| E.r. Squibb & Sons, L.L.C. | 39 | $631 |
| Pfizer | 40 | $490 |
| Incyte Corporation | 35 | $486 |
| LEO Pharma Inc. | 26 | $329 |
| Arcutis Biotherapeutics, Inc. | 19 | $299 |
| Galderma Laboratories, L.p. | 27 | $229 |
| Bristol Myers Squibb | 10 | $205 |
| Journey Medical Corporation | 6 | $145 |
| Biofrontera Inc. | 8 | $130 |
| Dermavant Sciences, Inc. | 5 | $93 |
| VYNE Pharmaceuticals Inc. | 3 | $80 |
| Genentech USA, Inc. | 4 | $76 |
| Paratek Pharmaceuticals, Inc. | 3 | $55 |
| Organon | 3 | $47 |
| Fresenius Kabi USA, LLC | 2 | $40 |
| Almirall LLC | 1 | $30 |
| Dermira, Inc. | 1 | $23 |
| Botanix SB Inc | 1 | $19 |
| Verrica Pharmaceuticals Inc. | 1 | $19 |
| Smith+Nephew | 1 | $18 |
| Mylan Institutional Inc. | 1 | $18 |
| Prugen, Inc. Pharmaceuticals | 1 | $17 |
| Sandoz | 1 | $15 |
| Merck | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$171,061 in reported general payments places this provider in the 95th percentile of 404 dermatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 140 | $2,922,624 |
| Humira(Cf) PenAdalimumab | 113 | $1,098,057 |
| TremfyaGuselkumab | 64 | $860,072 |
| Dupixent PenDupilumab | 156 | $626,470 |
| StelaraUstekinumab | 16 | $422,867 |
| RinvoqUpadacitinib | 64 | $401,235 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 40 | $363,101 |
| OtezlaApremilast | 54 | $258,328 |
| Cosentyx Unoready PenSecukinumab | 22 | $235,581 |
| Taltz AutoinjectorIxekizumab | 21 | $198,627 |
| Dupixent SyringeDupilumab | 44 | $174,514 |
| Bimzelx AutoinjectorBimekizumab-Bkzx | 11 | $165,917 |
| ZoryveRoflumilast | 12 | $14,709 |
| Fluorouracil | 179 | $10,761 |
| Tacrolimus | 94 | $9,741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya, Stelara | $64,903 | $1,282,93980 claims |
| AbbVieRinvoq | $78,156 | $401,23564 claims |
| AmgenOtezla | $855 | $258,32854 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $299 | $14,70912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 404 dermatology providers in Michigan.
Other dermatology in Sebewaing
- Linda Stein GoldWest Bloomfield$3.3M
- Kristi HawleyCaledonia$2.2M
- David AltmanWarren$1.9M
- Michael SiegelWaterford$708K
- Johann GudjonssonAnn Arbor$535K
- Michael DormanWest Bloomfield$433K
- Steven DaveluyDearborn$350K
- Benjamin WorkmanMidland$284K
- Diana WestgateKalamazoo$252K
- Christofer BuattiAuburn Hills$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.